Topics

manufacturers

People or companies who produce (manufacture) vaccines, drug, or other medical products.

2.4 Nonclinical Overview AZD1222
2.5 Clinical Overview: AZD1222 Marketing Authorisation Application - Primary Analysis (Data Cut-off 07 December 2020)
5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received through 28-FEB-2021
A cautionary note: Toxicity of polyethylene glycol 200 injected intraperitoneally into mice
Affidavit of LTC. Theresa Long M.D. in Support of a Motion for a Preliminary Injunction Order
AFTER ACTION REVIEW OF THE COVID-19 PANDEMIC: The Lessons Learned and a Path Forward
An Independent Analysis of the Manufacturing and Quality Issues of the BNT162b BioNTech/Pfizer Quasi-vaccine based on the European Medicines Agency’s Public Assessment Report (EPAR)
Anti-science case study: COVID-19 vaccines’ effectiveness and safety exaggerated
Approval letter: Biologics License Application (BLA) Approval for BioNTech (Pfizer) Manufacturing GmbH
At Least 55 Undeclared Chemical Elements Found in COVID-19 Vaccines from AstraZeneca, CanSino, Moderna, Pfizer, Sinopharm and Sputnik V, with PreciseICP-MS1
BioNTech RNA-Based COVID-19 Injections Contain Large Amounts Of Residual DNA Including An SV40 Promoter/Enhancer Sequence
BMF Investigation: FDA oversight of clinical trials is “grossly inadequate,” say experts
Cationic compounds used in lipoplexes and polyplexes for gene delivery
CBER Plans for Monitoring COVID-19 Vaccine Safety and Effectivenes
CDC Emails: Our Definition of Vaccine is "Problematic"
CDC Finally Released Its VAERS Safety Monitoring Analyses for COVID Vaccines via FOIA
Comirnaty Facts: Mechanisms of action and damage potential
Compilation of Donald Trump promoting COVID-19 vaccines
Corporate Rap Sheet — Johnson & Johnson
Court documents and clinical-trial documents for Pfizer, Inc. and Moderna, Inc.
COVID-19 Contracts
COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room
Covid-19 vaccines and treatments: we must have raw data, now
COVID-19: Information on HHS's Medical Countermeasures Injury Compensation Program
Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial
Covid-19: Should doctors recommend treatments and vaccines when full data are not publicly available?
Curing the pandemic of misinformation on COVID-19 mRNA vaccines through real evidence-based medicine - Part 2
Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID–19
Does the FDA think these data justify the first full approval of a covid-19 vaccine?
Down The Covid-19 Rabbit Hole: Independent Scientists And Physicians Unmask The Pandemic
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022
Emergency Use Authorization for Vaccines to Prevent COVID-19 - Guidance for Industry
Expedited COVID-19 vaccine trials: a rat-race with challenges and ethical issues
Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) — Emergency Use Authorization (EUA) of the Janssen COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19)
Fact Sheet for Recipients and Caregivers - Emergency Use Authorization (EUA) of the Pfizer-Biontech COVID-19 Vaccine to Prevent Coronavirus
Fact Sheet: Explaining Operation Warp Speed
FDA Briefing Document - Moderna COVID-19 Vaccine
FDA Briefing Document - Pfizer-BioNTech COVID-19 Vaccine
FDA Repays Industry by Rushing Risky Drugs to Market
FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine
Final Report of the Twenty-Second Statewide Grand Jury (Florida)
First case of postmortem study in a patient vaccinated against SARS-CoV-2
Forensic Analysis of the 38 Subject Deaths in the 6-Month Interim Report of the Pfizer/BioNTech BNT162b2 mRNA Vaccine Clinical Trial
Form S-1 Registration Statement Under the Securities Act of 1933: BioNTech SE
Form S-1 Registration Statement Under the Securities Act of 1933: Moderna, Inc.
Functionalized graphene oxide serves as a novel vaccine nano-adjuvant for robust stimulation of cellular immunity
Graphene and graphene oxide as nanomaterials for medicine and biology application
Graphene and the Immune System: A Romance of Many Dimensions
How Much Could COVID-19 Vaccines Cost the U.S. After Commercialization?
Injections from Hell?
535